Navigation Links
Researchers identify new protein markers that may improve understanding of heart disease
Date:3/30/2014

Researchers at the Intermountain Medical Center Heart Institute in Murray, Utah, have discovered that elevated levels of two recently identified proteins in the body are inflammatory markers and indicators of the presence of cardiovascular disease.

These newly identified markers of inflammation, GlycA and GlycB, have the potential to contribute to better understanding of the inflammatory origins of heart disease and may be used in the future to identify a heart patient's future risk of suffering a heart attack, stroke, or even death.

Inflammation occurs in the body in response to tissue damage, irritation, or infection. Inflammation is often associated with injury (i.e., sprained ankle), infection (i.e., strep throat), and auto-immune diseases (i.e., rheumatoid arthritis). However, it has been shown that inflammation is also a risk factor for heart disease.

"There are at least two benefits evident from this study," said J. Brent Muhlestein, MD, lead researcher and co-director of cardiovascular research at the Intermountain Medical Center Heart Institute. "First, a new marker of heart attack or stroke may help us to more effectively identify which patients are at risk. Second, now that we know GlycA and GlycB are important predictors of heart disease, we'll seek to understand more about the physiology of these proteins what causes them to increase and how we can we treat elevated levels."

Levels of GlycA and GlycB were determined from a blood test called nuclear magnetic resonance (NMR) spectroscopy, which was developed to determine the number of lipid particles contained in different cholesterol parameters.

Testing for GlycA and GlycB by NMR spectroscopy uses signals that arise from the binding of glucose molecules to a variety of circulating inflammatory proteins, especially fibrinogen, α1-antichymotrypsin, haptoglobin-1, α1-antitrypsin, complement C3 and α1-acid glycoprotein.

Like C-reactive protein, one of the most well-known and studied inflammatory markers shown to be associated with cardiovascular disease, GlycA and GlycB are acute phase proteins with plasma concentrations that increase or decrease in response to changes in the levels of inflammation throughout the body.

This is one of the first studies ever to evaluate the association of GlycA and GlycB to cardiovascular disease. In this study, almost 3,000 patients who underwent heart catheterization to determine the presence of coronary artery disease with a minimum of five years of follow-up were evaluated.

Of the 48 percent of heart patients who died, suffered a heart attack, stroke, or heart failure during follow-up, the majority had significantly higher baseline levels of GlycA and GlycB. Specifically, those with levels in the top 25 percent were more than 30 percent more likely to have an adverse cardiovascular event compared to those with levels in the lowest 25 percent, even after other risk factors were taken into account.

"The next step will be to determine how GycA and GlycB correlate with, or are independent of, other common inflammatory markers like C-reactive protein," said Dr. Muhlestein.


'/>"/>

Contact: Jess C. Gomez
jess.gomez@imail.org
801-718-8495
Intermountain Medical Center
Source:Eurekalert

Related biology news :

1. Two researchers known for identifying and treating bubble boy disease honored by March of Dimes
2. Researchers at IRB discover a key regulator of colon cancer
3. Researchers reveal the dynamics behind Arctic ecosystems
4. IRCM researchers uncover a new function for an important player in the immune response
5. UGA researchers explore function of cancer-causing gene
6. Researchers present comprehensive roadmap of blood cells
7. UT Southwestern ob/gyn researchers studying genetic factors in premature births
8. Researchers issue state-of-the-state on genetic-based testing & treatment for breast cancer
9. Miscarriage clues identified in new DNA test according to researchers at Montefiore and Einstein
10. Researchers uncover allergy-cancer connection
11. Vanderbilt diabetes researchers track cells ability to regenerate
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... December 1, 2016 The ... Voice), Future Technology (Iris Recognition System), Vehicle Type ... Global Forecast to 2021", published by MarketsandMarkets, the ... in 2016, and is projected to grow to ... of 14.06%.      (Logo: http://photos.prnewswire.com/prnh/20160303/792302) ...
(Date:11/30/2016)... CHICAGO , Nov. 30, 2016  higi ... a new partnership initiative targeting national brands, industry ... and reward their respective audiences for taking steps ... Since its inception in 2012, higi has built ... US, impacting over 38 million people who have ...
(Date:11/29/2016)... Nearly one billion matches per second with DERMALOG,s high-speed AFIS    ... ... DERMALOG is Germany's largest Multi-Biometric supplier: The company's Fingerprint ... ... Multi-Biometric supplier: The company's Fingerprint Identification System is part of an efficient ...
Breaking Biology News(10 mins):
(Date:12/8/2016)... ... December 08, 2016 , ... Opal ... provide essential device-to-computer interconnect using USB or PCI Express, announced the FOMD-ACV-A4, the ... FOMD-ACV-A4 is a small, thin, SODIMM-style module that fits a standard 204-pin SODIMM ...
(Date:12/8/2016)... 2016  Anaconda BioMed S.L., a pre-clinical stage medical ... generation neuro-thrombectomy system for the treatment of Acute Ischemic ... MD to join its Scientific Advisory Board (SAB). The ... of scientific and clinical experts to Anaconda BioMed S.L., ... BRAIN ® to its clinical phase. The SAB ...
(Date:12/8/2016)... ... December 08, 2016 , ... Microbial genomics leader, uBiome, joins ... one of just six company finalists in the Health & Medicine category. Over ... nominated as finalists in this year’s awards include Google, SpaceX, Oculus, and SolarCity. ...
(Date:12/8/2016)... , Dec. 8, 2016 Soligenix, Inc. (OTCQB: ... focused on developing and commercializing products to treat rare ... today that it will be hosting an Investor Webcast ... on the origins of innate defense regulators (IDRs) as ... of oral mucositis and the recently announced and published ...
Breaking Biology Technology: